If you have been reading about freeze-dried powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
| Property | Value | Notes |
|---|---|---|
| Typical subjects | Rats and mice | Animal models |
| Common routes | Injection and oral | Route varies by study |
| Reported dose range | Microgram to milligram per kg | Not standardized across work |
| Frequent endpoints | Tissue repair, angiogenesis | Marker-dependent |
| Human evidence | Limited | Mostly small or preliminary studies |
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
voters to be British subjects, male, 21 years of age and older, able to write their address and occupation, and then to fulfil the following financial requirements: (a) ownership of a registered mining claim in Southern Rhodesia, or (b) occupying immovable property worth £75, or (c) receiving wages or salary of £50 per annum in Southern Rhodesia. Six months' continuous residence was also required for qualifications (b) and (c). Following Cecil Rhodes's dictum of "equal rights for all civilised men", there was an implicit, albeit not an overt, racial component to the franchise, which effectively excluded a majority of native black people from the electorate via such means as property qualifications. The 1961 Constitution governed Southern Rhodesia and independent Rhodesia up until 1969, using the Westminster Parliamentary System modified by a system of separate voter rolls with differing property and education qualifications, without regard to race. Whites ended up with the majority of Assembly seats with Whites attaining 50 out of 66 seats. Blacks would only attain 16 out of the 66 seats in the Rhodesian Parliament. The 1969 republican constitution established a bicameral Parliament consisting of an indirectly elected Senate and a directly elected House of Assembly operated under a unitary system of government, effectively reserving the majority of seats for whites. The office of president had only ceremonial significance with the prime minister holding executive power.
joint involvement, designating the metacarpophalangeal joints, proximal interphalangeal joints, the interphalangeal joint of the thumb, second through fifth metatarsophalangeal joint and wrist as small joints, and shoulders, elbows, hip joints, knees, and ankles as large joints: Involvement of 1 large joint gives 0 points Involvement of 2–10 large joints gives 1 point Involvement of 1–3 small joints (with or without involvement of large joints) gives 2 points Involvement of 4–10 small joints (with or without involvement of large joints) gives 3 points Involvement of more than 10 joints (with involvement of at least 1 small joint) gives 5 points serological parameters – including the rheumatoid factor as well as ACPA – "ACPA" stands for "anti-citrullinated protein antibody": Negative RF and negative ACPA gives 0 points Low-positive RF or low-positive ACPA gives 2 points High-positive RF or high-positive ACPA gives 3 points acute phase reactants: 1 point for elevated erythrocyte sedimentation rate, ESR, or elevated CRP value (c-reactive protein) duration of arthritis: 1 point for symptoms lasting six weeks or longer The new criteria incorporate the growing understanding of and the advances in diagnosing and treating RA. In the "new" criteria, serology and autoimmune diagnostics carry major weight, as ACPA detection is appropriate to diagnose the disease in an early state, before joints destructions occur. Destruction of the joints seen in radiological images was a significant point in the ACR criteria from 1987.
=== Chronic toxicity === Ingestion of melamine may lead to reproductive damage, or bladder or kidney stones, which can lead to bladder cancer. A study in 1953 reported that dogs fed 3% melamine for a year had the following changes in their urine: (1) reduced specific gravity, (2) increased output, (3) melamine crystalluria, and (4) protein and occult blood. A survey commissioned by the American Association of Veterinary Laboratory Diagnosticians suggested that crystals formed in the kidneys when melamine combined with cyanuric acid, "don't dissolve easily. They go away slowly, if at all, so there is the potential for chronic toxicity."
== Periodic trends == The alkali metals are more similar to each other than the elements in any other group are to each other. For instance, when moving down the table, all known alkali metals show increasing atomic radius, decreasing electronegativity, increasing reactivity, and decreasing melting and boiling points as well as heats of fusion and vaporisation. In general, their densities increase when moving down the table, with the exception that potassium is less dense than sodium.
Sources: en.wikipedia.org
Alphavirus infection Asymmetric periflexural exanthem of childhood (unilateral laterothoracic exanthem) B virus infection Boston exanthem disease Bovine papular stomatitis Bowenoid papulosis Buffalopox Butcher's wart Chikungunya fever Condylomata acuminata Congenital rubella syndrome Cowpox Cytomegalic inclusion disease Dengue (Break-bone fever) Disseminated herpes zoster Eczema herpeticum (Kaposi's varicelliform eruption) Eczema vaccinatum Epidermodysplasia verruciformis Eruptive pseudoangiomatosis Erythema infectiosum (fifth disease, slapped cheek disease) Exanthem of primary HIV infection (acute retroviral syndrome) Farmyard pox Generalized vaccinia Genital herpes (herpes genitalis, herpes progenitalis) Gianotti–Crosti syndrome (infantile papular acrodermatitis, papular acrodermatitis of childhood, papulovesicular acrolocated syndrome) Giant condyloma acuminatum (Buschke–Löwenstein tumor, giant condyloma of Buschke–Löwenstein tumor) Hand-foot-and-mouth disease Heck's disease (focal epithelial hyperplasia) Hemorrhagic fever with renal syndrome Hepatitis B Hepatitis C Herpangina Herpes gladiatorum (scrum pox) Herpes simplex Herpes zoster oticus (Ramsay–Hunt syndrome) Herpetic keratoconjunctivitis Herpetic sycosis Herpetic whitlow HIV-associated pruritus Human monkeypox Human T-lymphotropic virus 1 infection Human tanapox Immune reconstitution inflammatory syndrome (immune recovery syndrome) Infectious mononucleosis (glandular fever) Inflammatory skin lesions following zoster infection (isotopic response) Intrauterine herpes simplex Kaposi sarcoma Lassa fever Lipschütz ulcer (ulcus vulvae acutum) Measles (rubeola, morbilli) Milker's nodule Modified varicella-like syndrome Molluscum contagiosum Myrmecia Neonatal herpes simplex Ophthalmic zoster Orf (contagious pustular dermatosis, ecthyma contagiosum, infectious labial dermatitis, sheep pox) Orf-induced immunobullous disease Orolabial herpes (herpes labialis) Papular purpuric gloves and socks syndrome Pigmented wart Postherpetic neuralgia (zoster-associated pain) Post-vaccination follicular eruption Progressive vaccinia (vaccinia gangrenosum, vaccinia necrosum) Pseudocowpox Recurrent respiratory papillomatosis (laryngeal papillomatosis) Rift Valley fever Roseola infantum (exanthem subitum, exanthema subitum, sixth disease) Roseola vaccinia Rubella (German measles) Sandfly fever (Pappataci fever, phlebotomus fever) Sealpox Varicella (chickenpox) Variola major (smallpox) Verruca plana (flat wart) Verruca plantaris (plantar wart) Verruca vulgaris (wart) Verrucae palmares et plantares Viral-associated trichodysplasia (ciclosporin-induced folliculodystrophy) Wasting syndrome West Nile virus infection Zoster (herpes zoster, shingles) Zoster sine herpete
In June 2023, The U.S. Food and Drug Administration (FDA) authorized for marketing Eroxon, an over-the-counter non-medicated hydro-alcoholic gel indicated for treatment of erectile dysfunction. In the clinical trial, erection was achieved by most men within ten minutes after applying the gel. The gel is manufactured by Futura Medical, a British medical company. The gel is regulated as a medical device and not as a drug, because its mode of action is a physical one and it doesn't have an active pharmaceutical ingredient. Eroxon is the first topical ED treatment sold over the counter in the United States. The gel had been on sale in Europe under a CE mark since 2023, and it reached American shops in October 2024. As of 2026, the gel is sold in the United States, United Kingdom, Europe, and several countries in Latin America and the Middle East.
On the one hand, God remains responsible as the creator of the world and is thus also the ultimate cause of suffering—at least in the sense that his creation of the world made suffering possible in the first place. On the other hand, there are situations in which no finite power can save or help human beings. For by definition, only God is the reality that can save us even in death—if he exists. But how can I ask for help from the very one who made my misery possible in the first place? Kermani sees no way to rationally justify this question. Rather, he describes those voices that do not want to abandon God even in misery. The fools he cites do not simply lament the terror of God. Instead, they remind God of the promises he once made in creation. They insist on God's faithfulness, which God describes and promises in His self-revelation. The fools are therefore not blind to reality. On the contrary, they consider all the questions about the reality of a loving God that every human being experiences on a daily basis. Their adherence to God does not dull their senses or take away the horror of suffering. But it enables them to face the abysses and terror of reality without, however, giving up hope. Belief in God thus operates as an imposition that can drive one to madness. At the same time, however, it appears as the last possibility for putting up with the world in its ambiguity without losing one's own humanity.
Sources: en.wikipedia.org
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.
Frequently measured outcomes include wound healing, blood vessel growth, and tissue repair markers. Some work examines gastrointestinal protection. The choice of endpoint depends on the model used.
Different routes of administration and different animal models require different amounts. Studies also use varied timelines and measurement methods. This variation makes it difficult to combine results into a single standardized figure.
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.